Metolazone Indications
Metolazone is indicated for treating salt and water retention in congestive heart failure, renal disease (including nephrotic syndrome and diminished renal function), and hypertension, either alone or combined with other antihypertensives 1.
Primary FDA-Approved Indications
The FDA label clearly delineates three main indications 1:
1. Edema Management
- Congestive heart failure with fluid retention: 5-20 mg once daily
- Renal disease-associated edema: 5-20 mg once daily, including nephrotic syndrome and states of diminished renal function
- Effective even with low glomerular filtration rate, unlike other thiazides
2. Hypertension
- Mild to moderate essential hypertension: 2.5-5 mg once daily
- Can be used as monotherapy or combined with other antihypertensive classes
- Onset of effect may take 3-4 days to 3-6 weeks
3. Pregnancy-Related Edema (Limited Indication)
- Only when edema is due to pathologic causes (not physiologic pregnancy edema)
- Short courses may be appropriate for extreme discomfort unrelieved by rest
- Not indicated for routine use or toxemia prevention in pregnancy
Contemporary Clinical Use: Diuretic-Resistant Heart Failure
The most important modern indication is as add-on therapy to loop diuretics in patients with refractory edema unresponsive to loop diuretics alone 2. The 2022 AHA/ACC/HFSA Heart Failure Guidelines provide a Class 1, Level B-NR recommendation that metolazone should be added to loop diuretics specifically for patients who do not respond to moderate- or high-dose loop diuretics 2.
Key Clinical Context:
- Sequential nephron blockade: Metolazone acts at the distal convoluted tubule while loop diuretics work at the loop of Henle, creating synergistic diuresis 2
- Reserve for true resistance: Should not be first-line; use only after loop diuretics at adequate doses have failed 2
- Low-dose strategy: Start with ≤5 mg daily to minimize electrolyte abnormalities 2, 3
Important Caveats and Pitfalls
Absorption Issues
Metolazone (Zaroxlyn formulation) has slow and erratic absorption, particularly reduced in heart failure patients 3, 4. This pharmacologic profile, combined with large volume of distribution and high renal clearance, creates the basis for effective combination therapy with loop diuretics.
Safety Monitoring Requirements
The combination of metolazone with loop diuretics produces potent diuresis requiring close surveillance 4:
- Electrolyte abnormalities: Clinically significant hypokalemia (<2.5 mM) or hyponatremia (<125 mM) occur in approximately 10% of treatment episodes 3
- Weight monitoring: Essential to avoid excessive diuresis
- If excessive diuresis occurs: Stop both drugs temporarily—do not simply reduce doses 4
Renal Function Considerations
Despite traditional teaching, metolazone produces diuretic response even with severely reduced GFR 5, 6. Small increases in serum creatinine may occur initially due to volume depletion rather than true nephrotoxicity 6.
Comparative Effectiveness
When comparing thiazide-type diuretics for diuretic resistance, metolazone appears as effective as intravenous chlorothiazide with comparable safety profiles 7, 8. Given the substantial cost advantage of oral metolazone over IV chlorothiazide, metolazone represents a practical first choice for sequential nephron blockade 8.